全文获取类型
收费全文 | 16567篇 |
免费 | 1059篇 |
国内免费 | 359篇 |
专业分类
耳鼻咽喉 | 188篇 |
儿科学 | 361篇 |
妇产科学 | 324篇 |
基础医学 | 1442篇 |
口腔科学 | 320篇 |
临床医学 | 1425篇 |
内科学 | 1204篇 |
皮肤病学 | 420篇 |
神经病学 | 229篇 |
特种医学 | 644篇 |
外国民族医学 | 4篇 |
外科学 | 5696篇 |
综合类 | 2607篇 |
预防医学 | 444篇 |
眼科学 | 98篇 |
药学 | 962篇 |
8篇 | |
中国医学 | 536篇 |
肿瘤学 | 1073篇 |
出版年
2024年 | 10篇 |
2023年 | 174篇 |
2022年 | 218篇 |
2021年 | 442篇 |
2020年 | 471篇 |
2019年 | 406篇 |
2018年 | 452篇 |
2017年 | 520篇 |
2016年 | 482篇 |
2015年 | 485篇 |
2014年 | 1021篇 |
2013年 | 904篇 |
2012年 | 869篇 |
2011年 | 1122篇 |
2010年 | 968篇 |
2009年 | 853篇 |
2008年 | 914篇 |
2007年 | 1011篇 |
2006年 | 921篇 |
2005年 | 829篇 |
2004年 | 694篇 |
2003年 | 587篇 |
2002年 | 536篇 |
2001年 | 466篇 |
2000年 | 338篇 |
1999年 | 259篇 |
1998年 | 217篇 |
1997年 | 188篇 |
1996年 | 176篇 |
1995年 | 160篇 |
1994年 | 140篇 |
1993年 | 126篇 |
1992年 | 120篇 |
1991年 | 102篇 |
1990年 | 71篇 |
1989年 | 87篇 |
1988年 | 81篇 |
1987年 | 69篇 |
1986年 | 62篇 |
1985年 | 76篇 |
1984年 | 55篇 |
1983年 | 48篇 |
1982年 | 61篇 |
1981年 | 62篇 |
1980年 | 42篇 |
1979年 | 16篇 |
1978年 | 13篇 |
1977年 | 19篇 |
1976年 | 18篇 |
1973年 | 9篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
71.
AimThere is no consensual indication for surgical resection after diagnosis on per-cutaneous biopsy of borderline breast lesions (B3). We evaluate under-evaluation rate of per-cutaneous biopsy and predictive factors of under-evaluation. We analyze accuracy of reported decision-making tools.MethodsWe conduct a prospective multicentric study including, atypic-ductal hyperplasia (ADH), atypic-lobular hyperplasia (ALH), atypic-cylindro-cubic metaplasia (FEA), papilloma, radial scars (RS) and phyllod tumors. When several B3 lesions were associated, the more severe lesion was used to classify the lesion. We determined breast cancers (BC) rate and histologic type.Among 478 patients, 518 B3 lesions were studied: 15.1% (78) FEA, 48.6% (252) ADH, 16.8% (n = 87) ALH, 5.4% (n = 28) RS, 12% (n = 62) papilloma, 0.8% (n = 4) phyllod tumors and 0,8% (n = 4) with a suspicious low grade DCIS. More than 1 lesion was identified in 31.9% (165) of cases.A surgical resection was performed for 86.3% (447/518) lesions. Significant factors of surgical resection were: residual micro-calcification after biopsy (OR: 2.7) and type of B3 lesion.ResultsOverall BC rate was 15.3% (68/445) with 79.4% (54) in-situ carcinomas. According to B3 lesions, BC rates were 12.9% for FEA, 20% for ADH, 11.6% for ALH, 3.7% for RS, 8.8% for papilloma and 25% for suspicious in-situ carcinoma.A score has been calculated and patients were distributed in 3 groups. Patient's rates without BC were respectively: 100%, 80.4% and 80.6% (p = 0.029).ConclusionIn conclusion, it could be suggested to avoided complementary surgical resection in case of good radio-pathologic concordance and low probability of BC. 相似文献
72.
《Journal of vascular and interventional radiology : JVIR》2021,32(8):1113-1118
PurposeTo assess perioperative blood loss following prostatic artery embolization (PAE) before surgery in patients undergoing simple prostatectomy.MethodsA retrospective chart review was used to identify 63 patients (mean age, 65.3 ± 8.0 years) with prostatic hypertrophy and severe lower urinary tract symptoms who underwent prostatectomy from September 2014 to December 2019, 18 (28.5%) of whom underwent PAE before surgery. Demographic data, pertinent laboratory results, procedural or operative information, hospital course details, and pathology reports were obtained. A 2:1 propensity score‒matching analysis was performed to compare intraoperative blood loss in patients who underwent prostatectomy alone with intraoperative blood loss in those who first underwent bilateral PAE before surgery.ResultsSixteen (89%) of the 18 patients underwent bilateral PAE before surgery. Thirty-two patients who underwent prostatectomy without embolization before surgery were selected for the 2:1 propensity score‒matched analysis based on age, race, surgery type, prostate gland size, and comorbidities. The mean estimated blood loss (EBL) for prostatectomy alone was 545 ± 380 mL (mean ± standard deviation). There was a statistically significant reduction in the EBL for patients who underwent bilateral PAE (303 ± 227 mL, P < .01). The operative time was also significantly decreased for patients who underwent PAE before surgery (P < .05). For patients who underwent PAE, there were no complications related to the procedure.ConclusionsBilateral PAE before surgery appears to be safe and may be effective in reducing perioperative bleeding and operative time. 相似文献
73.
Kurt J. Pfeifer Angela Selzer Carlos E. Mendez Christopher M. Whinney Barbara Rogers Vinaya Simha Dennis Regan Richard D. Urman Karen Mauck 《Mayo Clinic proceedings. Mayo Clinic》2021,96(6):1655-1669
Perioperative medical management is challenging due to the rising complexity of patients presenting for surgical procedures. A key part of preoperative optimization is appropriate management of long-term medications, yet guidelines and consensus statements for perioperative medication management are lacking. Available resources utilize the recommendations derived from individual studies and do not include a multidisciplinary focus or formal consensus. The Society for Perioperative Assessment and Quality Improvement (SPAQI) identified a lack of authoritative clinical guidance as an opportunity to utilize its multidisciplinary membership to improve evidence-based perioperative care. SPAQI seeks to provide guidance on perioperative medication management that synthesizes available literature with expert consensus. The aim of this Consensus Statement is to provide practical guidance on the preoperative management of endocrine, hormonal, and urologic medications. A panel of experts with anesthesiology, perioperative medicine, hospital medicine, general internal medicine, and medical specialty experience was drawn together and identified the common medications in each of these categories. The authors then utilized a modified Delphi approach to critically review the literature and generate consensus recommendations. 相似文献
74.
75.
《Journal of vascular and interventional radiology : JVIR》2022,33(5):558-563.e1
This study evaluated detectable nontarget embolization (NTE) during prostatic artery embolization (PAE) and the safety and efficacy of using radiopaque particles in PAE. Ten patients aged >40 years with prostate glands of >50 mL and refractory lower urinary tract symptoms were analyzed. Unenhanced computed tomography scans at baseline and at 3 months after PAE, using 40–90-μm radiopaque spherical embolic beads, were compared to assess the NTE. Growth models evaluated changes from baseline to 3, 6, and 12 months in International Prostate Symptom Score (IPSS), peak urine flow rate (Qmax), quality of life (QoL), International Index of Erectile Function (IIEF), and postvoid residual (PVR). The IPSS, QoL, and Qmax improved at all time points (P < .05), with no trend in PVR or IIEF. Adverse events that occurred were minor. Radiographic NTE was seen in all patients, correlating at times with postprocedural symptoms (eg, rectal pain). Symptoms were not correlated with the NTE in some patients, whereas other patients remained asymptomatic despite NTE. 相似文献
76.
《Diagnostic Histopathology》2022,28(8):369-379
Sampling of the endometrium, via biopsy or dilation and curettage, is an important diagnostic tool in a wide variety of clinical scenarios, ranging from infertility and abnormal uterine bleeding to cancer surveillance in high-risk populations. This review describes the most common methods for endometrial sampling used currently and discusses the issue of specimen adequacy from an evidence-based perspective. It also focuses on select benign conditions involving the endometrium in the setting of abnormal uterine bleeding, ranging from anatomic/structural lesions to patterns indicative of a dysfunctional menstrual cycle. The topic of endometrial sampling evaluation in the context of recurrent pregnancy loss is also discussed, with insights on documentation of endometrial changes during the ovulatory phase and the diagnosis of endometritis. 相似文献
77.
《Diagnostic Histopathology》2022,28(2):69-78
Well-differentiated hepatocellular mass-lesions in non-cirrhotic livers have a differential diagnosis of focal nodular hyperplasia, regenerative hepatic pseudotumors, hepatic adenoma, hepatocellular carcinoma, and fibrolamellar carcinoma. Despite significant advances in characterizing these pseudotumors and tumors, they remain a diagnostic challenge, especially on needle biopsy. This review focuses on a systematic diagnostic approach, one that allows confident diagnosis of these lesions. 相似文献
78.
Transcriptional profiling reveals gene expression changes associated with inflammation and cell proliferation following short‐term inhalation exposure to copper oxide nanoparticles 下载免费PDF全文
79.
Jae Hoon Chung Cheol Young Oh Jae Heon Kim U-Syn Ha Tae Hyo Kim Seung Hwan Lee 《Current medical research and opinion》2018,34(10):1793-1801
Objective: To verify the efficacy and safety of tamsulosin 0.4?mg and tamsulosin 0.2?mg compared with those of placebo in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).Methods: A total of 494 patients from multiple centers participated in this double-blind, randomized, phase 3 trial. Eligible patients were randomly assigned to the tamsulosin 0.4?mg group, tamsulosin 0.2?mg group or placebo group. The International Prostate Symptom Score (IPSS), maximum flow rate (Qmax), post-void residual (PVR) urine volume, blood pressure, heart rate and adverse events were compared among the three groups at 4, 8 and 12 weeks.Results: A total of 494 BPH patients were analyzed. There were no differences in the baseline characteristics among the three groups. After 12 weeks of treatment, total IPSS was improved in the 0.2?mg and 0.4?mg tamsulosin groups; however, the extent of improvement was greater in the 0.4?mg group than in the 0.2?mg group (0.4?mg: ?9.59 vs. 0.2?mg: ?5.61; least-squares mean difference [95% confidence interval]: ?3.95 [?5.01, ?2.89], p?.0001). In addition, in the patients with severe symptoms (IPSS ≥20), total IPSS was improved the most in the 0.4?mg group (?11.27?±?5.00, p?.0001). Qmax and PVR were improved in the 0.4?mg and 0.2?mg groups; however, the differences were not statistically significant between treatment groups. No patients experienced any serious adverse effects in any of the three groups.Conclusions: Tamsulosin 0.4?mg and 0.2?mg appear to be superior to placebo treatment, and tamsulosin 0.4?mg is more effective than 0.2?mg in terms of total IPSS improvement. Tamsulosin 0.4?mg has favorable efficacy and tolerability in Asian men with symptomatic BPH.ClinicalTrials.gov Identifier: NCT02390882. 相似文献
80.
目的 探讨氟哌噻吨美利曲辛片对继发性良性阵发性位置性眩晕(bnign proxysmal psitional vrtigo,BPPV)老年患者残余头晕症状的影响。方法 收集2014年1月—2016年9月嘉兴市第一医院神经内科治疗的84例继发性BPPV老年患者(年龄>65周岁)的临床资料,分为氟哌噻吨美利曲辛片治疗组(n=42)和常规治疗组(n=42)。比较2组残余头晕的持续时间及治疗前,治疗后第3天、第1周、第2周的眩晕障碍量表(Dizziness Handicap Inventory,DHI)分数。结果 和常规治疗组相比,氟哌噻吨美利曲辛片治疗组残余头晕症状持续时间明显较短(P=0.002)。复位成功后,与常规治疗组相比,氟哌噻吨美利曲辛片组治疗后第1周和第2周的DHI分数明显降低(P分别为0.040和0.030)。结论 氟哌噻吨美利曲辛片治疗继发性BPPV,可使残余头晕的持续时间明显缩短,治疗1周和2周后DHI评分降低。 相似文献